Most Read Articles
Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Roshini Claire Anthony, 27 May 2020

The use of a vaginal cleansing intervention prior to Caesarean delivery reduced the incidence of surgical site infections (SSIs), according to a study presented at ACOG 2020. However, the addition of intravenous (IV) azithromycin prophylaxis had no added impact on SSI rates. 

Jairia Dela Cruz, 27 Mar 2020
Use of antioxidants for treating male factor infertility appears to be of little benefit, improving neither semen parameters nor DNA integrity, according to the results of the Males, Antioxidants and Infertility (MOXI) trial.

Rituximab appears to be effective in systemic rheumatoid vasculitis

28 Apr 2020

Treatment with rituximab for systemic rheumatoid vasculitis (RV) results in complete remission (CR) in 62 percent of patients and partial response (PR) in 38 percent, a study has shown.

Medical charts of 17 patients (mean age, 59 years; 59 percent female) treated with rituximab for systemic RV from 2000 to 2017 were retrospectively reviewed. Analysis was performed on clinical characteristics, outcomes and adverse effects.

At RV diagnosis, 82 percent of patients had positive rheumatoid factor. Median Birmingham Vasculitis Activity Score for rheumatoid arthritis at the time of rituximab initiation was 4.0 (interquartile range, 2.0–7.5). Of the patients, eight (47 percent) presented with RV in the skin, two (12 percent) had mononeuritis multiplex, two (12 percent) experienced inflammatory ocular disease, and five (29 percent) had multiple organ systems affected by RV.

Rituximab was used for induction therapy in eight patients (47 percent), relapsing RV in four (24 percent), second-line therapy in two (12 percent), and salvage therapy or in combination with another medication in three (18 percent).

At 3 months, CR was achieved by two (13 percent) of 15 patients with available follow-up data and PR by 10 (67 percent). At 6 months, CR and PR were achieved by six (40 percent) and eight (53 percent) patients, whereas one showed no response. Eight (62 percent) of 13 patients with available records achieved CR and five (38 percent) had PR at 12 months.

“Further evidence is needed to inform treatment for patients with RV,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Roshini Claire Anthony, 27 May 2020

The use of a vaginal cleansing intervention prior to Caesarean delivery reduced the incidence of surgical site infections (SSIs), according to a study presented at ACOG 2020. However, the addition of intravenous (IV) azithromycin prophylaxis had no added impact on SSI rates. 

Jairia Dela Cruz, 27 Mar 2020
Use of antioxidants for treating male factor infertility appears to be of little benefit, improving neither semen parameters nor DNA integrity, according to the results of the Males, Antioxidants and Infertility (MOXI) trial.